Work

The ELR+CXCL chemokines and their receptors CXCR1/CXCR2

Year: 2014

Type: article

Abstract: The long-term efficacy of anti-angiogenesis drugs targeting vascular endothelial growth factor (VEGF) and VEGF receptors in the treatment of renal cell carcinoma (RCC) has been lacking. We have shown that the ELR+CXCL cytokines and their (C-X-C) chemokine receptors, namely CXCR1 and CXCR2, stimulate cancer cell proliferation, tumor inflammation, and angiogenesis. Hence, this essential molecular nexus regulating cancer growth represents a key therapeutic target.

Source: OncoImmunology

DOI: 10.4161/onci.28399

Authors: Sandy Giuliano, Mélanie Guyot, Renaud Grépin, Gilles Pagès

Institutions: Centre National de la Recherche Scientifique, Inserm, Institut de Recherche sur le Cancer et le Vieillissement de Nice, Université Nice Sophia Antipolis, Scientific Centre of Monaco

Language: English

Topic: Chemokine receptors and signaling

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913